Bird & Bird is pleased to announce that its Hong Kong office acted as Hong Kong legal advisers to the largest shareholder of The Women’s Clinic Group Limited (寶德醫務集團有限公司) (“TWCG“) in connection with the sale of its controlling stake in TWCG to Templewater.
TWCG is one of Hong Kong’s largest and most established private women’s healthcare specialist groups. Today, the group operates a network of six clinics, three IVF laboratories, and one blood laboratory in Hong Kong and Singapore, providing fertility treatment, obstetrics and gynaecology, traditional Chinese medicine, and related healthcare services to patients across the region.
Templewater is an Asia-based alternative asset manager founded in 2018. The firm provides its investors, which include global institutions, family offices and high-net worth individuals, with two core pan-Asia strategies: (a) private equity focusing on mid-market buyout, and (b) energy transition venture growth. Templewater’s mission is to provide financial and human capital, operational expertise, a corporate governance framework, and integrity to build leading businesses.
The deal was led by James Fong (Partner, Hong Kong), supported by Philip Chui (Senior Associate, Hong Kong) and Ivan Wong (Associate, Hong Kong).
“The Women’s Clinic Group is one of the most recognised women’s health platforms in Hong Kong, and this transaction underscores the sophistication of the healthcare M&A market in the region,” remarked James Fong, Partner at Bird & Bird Hong Kong. “We are delighted to have guided our client to a successful outcome.”
